FDA Warns Novo Nordisk Over Failure to Report Serious Side Effects of Ozempic and Wegovy

Key Facts

1The FDA issued a warning to Novo Nordisk regarding unreported cases of side effects.

2Cases include two deaths and one suicide linked to patients taking semaglutide (Ozempic and Wegovy).

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk for failing to properly report serious adverse events related to its popular GLP-1 medications. According to reports, the company neglected to document specific cases including two deaths and one suicide among patients using Ozempic and Wegovy. These drugs, which contain the active ingredient semaglutide, have become global blockbusters for weight loss and diabetes management. This regulatory scrutiny raises significant concerns regarding the company's compliance with safety reporting standards and potential legal liabilities. Market analysts expect this development to weigh heavily on Novo Nordisk's stock performance as investors assess the reputational and regulatory risks. Furthermore, the warning may trigger broader oversight across the healthcare sector regarding modern obesity and diabetes treatments.